Fulcrum Therapeutics (NASDAQ:FULC) Downgraded to Hold Rating by Cantor Fitzgerald

Cantor Fitzgerald lowered shares of Fulcrum Therapeutics (NASDAQ:FULC) from a strong-buy rating to a hold rating in a report published on Tuesday morning,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Leerink Partners downgraded Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price for the company. in a report on Tuesday. Truist Financial downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Tuesday. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price for the company. in a report on Tuesday. Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd. Finally, HC Wainwright downgraded Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $3.14 on Tuesday. The stock has a fifty day moving average price of $7.23 and a 200 day moving average price of $9.22. Fulcrum Therapeutics has a 1-year low of $2.83 and a 1-year high of $15.74. The company has a market cap of $209.22 million, a PE ratio of -2.73 and a beta of 2.93.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.06. Analysts anticipate that Fulcrum Therapeutics will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at $30,000. Meeder Asset Management Inc. purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at $39,000. Quarry LP purchased a new position in shares of Fulcrum Therapeutics in the third quarter valued at $35,000. Persistent Asset Partners Ltd purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at $75,000. Finally, Summit Securities Group LLC purchased a new position in shares of Fulcrum Therapeutics in the first quarter valued at $53,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Trending Headlines about Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Negative Sentiment: Fulcrum halted its pociredir program after FDA feedback raised serious safety concerns, wiping out its lead clinical asset and prompting a strategic review that could include a sale or merger. Reuters: Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
• Negative Sentiment: Multiple law firms launched investigations into whether Fulcrum and its executives violated securities laws after the stock’s steep drop, adding legal overhang and investor uncertainty. PR Newswire: Fulcrum Therapeutics, Inc. Investigation Initiated
• Negative Sentiment: Several analysts cut ratings, including downgrades from Cantor Fitzgerald, Leerink Partners, Stifel, and HC Wainwright, reflecting a sharply less optimistic outlook after the program termination. Tickerreport.com: Fulcrum Therapeutics was downgraded by Cantor Fitzgerald

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.